Publication | Closed Access

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Phase 1BMedicinePathologyHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyClinical Activity